Checkpoint Therapeutics to Attend H.C. Wainwright 2nd Annual BioConnect Investor Conference

28 June 2024

WALTHAM, Mass., May 13, 2024-- Checkpoint Therapeutics, Inc. ("Checkpoint") (Nasdaq: CKPT) announced that its President and CEO, James Oliviero, will engage in a fireside chat at the H.C. Wainwright 2nd Annual BioConnect Investor Conference. This event, held at NASDAQ, is scheduled for Monday, May 20, 2024, at 12:30 p.m. ET. Additionally, Checkpoint will partake in in-person one-on-one meetings throughout the conference.

A webcast of the fireside chat will be accessible on the News & Events page within the Investors section of Checkpoint’s website for approximately 30 days following the event.

About Checkpoint Therapeutics

Checkpoint Therapeutics, Inc. is a clinical-stage company specializing in immunotherapy and targeted oncology. The firm is committed to acquiring, developing, and commercializing innovative therapies for patients dealing with solid tumor cancers. 

Checkpoint's leading antibody product candidate, cosibelimab, is designed to be a best-in-class anti-PD-L1 antibody. Licensed from the Dana-Farber Cancer Institute, cosibelimab is being investigated as a potential treatment for patients with specific recurrent or metastatic cancers, including metastatic and locally advanced cutaneous squamous cell carcinoma (cSCC).

In addition to cosibelimab, Checkpoint is also focusing on its primary small-molecule, targeted anti-cancer agent, olafertinib (previously known as CK-101). Olafertinib is a third-generation epidermal growth factor receptor (EGFR) inhibitor. It is being studied as a potential new treatment option for patients with EGFR mutation-positive non-small cell lung cancer.

Checkpoint Therapeutics is based in Waltham, MA, and was established by Fortress Biotech, Inc. (Nasdaq: FBIO). 

How to obtain the latest research advancements in the field of biopharmaceuticals?

In the Synapse database, you can keep abreast of the latest research and development advances in drugs, targets, indications, organizations, etc., anywhere and anytime, on a daily or weekly basis. Click on the image below to embark on a brand new journey of drug discovery!